Tamar Schiff

Tamar Schiff

Auto-generated profile, based on publicly available information

Tamar Schiff

Department of Population Health, NYU Grossman School of Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Xenotransplantation
Verified
Journal Article
Open access
PDF file
DHDaniel J. Hurst
Daniel J. Hurst
LPLuz Padilla
Luz Padilla
DRDaniel Rodger
Daniel Rodger
TSTamar Schiff
Tamar Schiff
DCDavid K. C. Cooper
David K. C. Cooper
With decades of pre‐clinical studies culminating in the recent clinical application of xenotransplantation, it would appear timely to provide recommendations for operationalizing oversight of xenotransplantation clinical trials. Ethical issues with clinical xenotransplantation have been described for decades, largely centering on animal welfare, the risks posed to the recipient, and public health risks posed by potential spread of xenozoonosis. Much less attention has been given to considerations relating to potentially elevated risks faced by those who may care for or otherwise have close contact with xenograft recipients. This paper examines the ethical and logistical issues raised by the potential exposure to xenozoonotic disease faced by close contacts of xenotransplant recipients—defined herein as including but not limited to caregivers, household contacts, and sexual partners—which warrants special attention given their increased risk of exposure to infection compared to the general public. We discuss implications of assent or consent by these close contacts to potentially undergo, along with the recipient, procedures for infection screening and possible quarantine. We then propose several options and recommendations for operationalizing oversight of xenotransplantation clinical trials that could account for and address close contacts’ education on and agency regarding the risk of xenozoonosis.

16 April 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
VTVasishta S. Tatapudi
Vasishta S. Tatapudi
AMAprajita Mattoo
Aprajita Mattoo
TSTamar Schiff
Tamar Schiff
SMSapna A. Mehta
Sapna A. Mehta
ESEdward Y. Skolnik
Edward Y. Skolnik
RMRobert A. Montgomery
Robert A. Montgomery
The scarcity of transplantable organs represents a worldwide public health crisis, and as a result, thousands of people with kidney failure die waiting for a transplant each year. Xenotransplantation involves transplanting organs from an animal source into humans, offering a potential solution to this significant unmet need. Indeed, if there is a limitless supply of organs, many more patients who do not meet the current criteria for transplant eligibility could also be considered as candidates. Although there are examples of attempts to transplant animal tissues or organs into humans dating back over 300 years, none were successful due to cross-species immunologic incompatibility. Even so, significant advances in genetic engineering and the emergence of novel immunosuppressive agents have spurred impressive improvements in xenograft survival in preclinical studies involving nonhuman primates. Furthermore, recent reports of genetically modified pig kidney and heart xenotransplants in human decedents and living recipients on a compassionate use basis have provided impetus to advancing the field toward first-in-human trials. However, studies in nonhuman primates and humans thus far have described adaptive as well as innate immune-mediated xenograft injury. Understanding the mechanistic aspects of these responses at the cellular and molecular levels is critical to the development of targeted genetic modifications and innovative therapeutic strategies aimed at preventing rejection and inducing tolerance. Moreover, the physiologic components of the bidirectional communication between the human host and pig xenograft must also be understood and manipulated. Here, we review the breakthroughs in kidney xenotransplantation in the past few decades and highlight the immunologic hurdles that have yet to be overcome.

1 November 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
TSTamar Schiff
Tamar Schiff
BPBrendan Parent
Brendan Parent
IDIan Dittmer
Ian Dittmer
WHWayne Hawthorne
Wayne Hawthorne
IKIvo Kwon
Ivo Kwon
RPRichard N. Pierson
Richard N. Pierson


2 June 2024 in The American Journal of Bioethics
Verified
Journal Article
Closed access
TSTamar Schiff
Tamar Schiff
ACArthur Caplan
Arthur Caplan